PrefLens: Position Artefacts and Convergent Validity in LLM Preference Elicitation

Hafiza Hajrah Rehman, Ameesha

PrefLens investigates whether different methods of measuring LLM preferences produce consistent results or are distorted by measurement artefacts. Across multiple models and elicitation methods, we find that option position can create apparent preference signals, obscure agreement between methods, and affect models differently. Our results highlight the need for order counterbalancing and position-aware diagnostics when studying LLM preferences.

Reviewer's Comments

Reviewer's Comments

Arrow
Arrow
Arrow

This project asks an important methodological question: do different ways of measuring apparent LLM preferences actually recover the same signal, or can the measurement procedure itself create what looks like a preference? The authors compare several elicitation methods across multiple models and then conduct controlled follow-up experiments specifically targeting position effects.

One of the strongest parts of the project is the attention given to experimental controls. The finding that Qwen's pairwise preference signal could be completely explained by display position is particularly striking. The follow-up studies are also well designed, using exact order counterbalancing and the same inference provider when comparing GPT-OSS 20B and 120B. It is also a strength that the authors report when their original hypotheses were wrong rather than trying to reinterpret the results to fit them.

The main limitation is the relatively small number of preference items and models. The main cross-method comparison is based on only ten shared items, which makes correlations and model-to-model differences more sensitive to the particular items selected. Gemini also did not complete one of the four elicitation methods, so the full design was not available consistently across all models.

Some findings should also be interpreted cautiously. The position-adjusted improvement for Llama is exploratory and only applies to self-report and pairwise choice, rather than all four methods. In addition, the cost trade-off method did not behave as originally expected, requiring the authors to change how that measure was summarized. These issues are clearly acknowledged, but they reduce how broadly the current results can be generalized.

Overall, this is a thoughtful and technically careful project with a useful practical message: preference measurements should not be trusted without checking whether option order is driving the result. The study would be even stronger with a much larger set of preference items, more model families, and exact counterbalancing built into every elicitation method from the beginning.

Strong methods work. Qwen's order-adjusted content signal is exactly 0.000 on all twelve items implies the whole measured 'preference' turning out to be display position is a critical way to view elicitation as measurement bias.

Pre-registered H1 and H2 and reported both as rejected, bootstrapped over items instead of API calls. Counterbalanced exactly in Studies 2b and 3. And declined to claim equivalence in Study 3 because you hadn't pre-registered a margin.

One thing: Your headline convergence number (Gemini, rho = +0.868) is the one result you never ran through your own position/content decomposition, and it comes from the study whose randomised design left 22.7% of trade-off cells without a matched order. And high cross-method agreement is equally consistent with a shared response heuristic, so you need a discriminant check for convergence.

Cite this work

@misc {

title={

(HckPrj) PrefLens: Position Artefacts and Convergent Validity in LLM Preference Elicitation

},

author={

Hafiza Hajrah Rehman, Ameesha

},

date={

},

organization={Apart Research},

note={Research submission to the research sprint hosted by Apart.},

howpublished={https://apartresearch.com}

}

Recent Projects

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

PROTEUS (PROTein Evaluation for Unusual Sequences): Structure-Informed Safety Screening for de novo and Evasion-Prone Protein-Coding Sequences

AI protein design tools like RFdiffusion, ProteinMPNN, and Bindcraft make it trivial to produce low-homology sequences that fold into active, potentially hazardous architectures. However, sequence homology-based biosafety screening tools cannot detect proteins that pose functional risk through structurally novel mechanisms with no sequence precedent. We present a tiered computational pipeline that addresses this gap by combining MMseqs2 sequence alignment with structure-based comparison via FoldSeek and DALI against curated toxin databases totaling ~34,000 entries. AlphaFold2-predicted structures are screened for both global fold similarity (FoldSeek) and local active/allosteric site geometry (DALI), capturing convergent functional hazards that sequence screening misses. The pipeline was validated against a panel of toxins, benign proteins, structural mimics, and de novo-designed Munc13 binders, as well as modified ricin variants with residue substitutions. We additionally tested robustness to partial-synthesis evasion, where a bad actor submits multiple shorter coding sequences intended for downstream reassembly into a full toxin-coding gene. We found that while sequence-based screening did not identify any de novo ricin analogues with high certainty, the combined pipeline with FoldSeek and DALI identified all 24 tested de novo ricins as toxic.

Read More

OliGraph: graph-based screening of large oligopools

Existing synthesis screening tools cannot evaluate short oligonucleotide pools, whose overlapping fragments can be reassembled into regulated sequences via polymerase cycling assembly (PCA) yet fall below gene-length detection thresholds. We present OliGraph, an open-source tool that constructs a bi-directed overlap graph from an oligonucleotide pool and extracts contigs for downstream gene-length screening. An optional PCA mode retains only cross-strand overlaps consistent with PCA chemistry. We validated OliGraph in a blinded study across ten simulated pools (70–9,184 oligonucleotides, 30–300 bp) spanning four risk categories. BLAST screening of individual oligonucleotides failed to identify sequences of concern in most pools: three returned zero hits, and vector noise obscured true positives in the remainder. After OliGraph assembly, contig-level BLAST matched the longest assembled sequences (up to 1,905 bp) to sequences of concern at 97–100% identity. In one pool, assembly collapsed 1,634 individual BLAST results into 10 hits from a single contig, all assigned to the same source organism. PCA mode correctly distinguished assemblable from non-assemblable fragments within the same pool. Two pools with no assemblable structure yielded no contigs. OliGraph processed all pools in under 0.2 seconds, fast enough for real-time order screening and consistent with proposals to bring oligonucleotide orders within the scope of synthesis screening regulation.

Read More

BioRT-Bench: A Multi-Attack Red-Teaming Benchmark for Bio-Misuse Safeguards in Frontier LLMs

Frontier AI laboratories are expected to maintain safeguards against biological misuse, but whether deployed models actually refuse bio-misuse queries under adversarial pressure is largely unmeasured in the public literature. We introduce BioRT-Bench, a benchmark that runs four attack methods (direct request, PAIR, Crescendo, and base64 encoding) against four frontier models (Claude Sonnet 4.6, GPT-5.4, DeepSeek V4-flash, Kimi K2.5) across 40 prompts spanning five biosecurity-relevant categories. Responses are scored by a calibrated judge extending StrongREJECT with two bio-specific dimensions: specificity and actionability. We measure Attack Success Rate (ASR), where 0 means the model fully refused and 1 means it provided specific, actionable bio-misuse content. Our results reveal a sharp robustness divide: Chinese frontier models (DeepSeek, Kimi) have under 5% refusal rates even under direct request (ASR 0.88 and 0.79), while Western models (Claude, GPT) maintain substantially stronger safeguards (ASR 0.15 and 0.16). Crescendo is the most effective attack across all models, both in bypassing refusal and in eliciting actionable content. Claude Sonnet 4.6 is the most robust model tested, achieving 100% refusal against base64-encoded prompts.

Read More

This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.
Apart Research logo

Sign up to stay updated on the
latest news, research, and events

Google Scholar icon

Apart Research Inc · 1500 N Grant St, Ste R, Denver, CO 80203 · +1 (720) 408-1923

Apart Research logo

Sign up to stay updated on the
latest news, research, and events

Google Scholar icon

Apart Research Inc · 1500 N Grant St, Ste R, Denver, CO 80203 · +1 (720) 408-1923

Apart Research logo

Sign up to stay updated on the
latest news, research, and events

Google Scholar icon

Apart Research Inc · 1500 N Grant St, Ste R, Denver, CO 80203 · +1 (720) 408-1923

This work was done during one weekend by research workshop participants and does not represent the work of Apart Research.
Apart Research logo

Sign up to stay updated on the
latest news, research, and events

Google Scholar icon

Apart Research Inc · 1500 N Grant St, Ste R, Denver, CO 80203 · +1 (720) 408-1923